Real-life experience with benralizumab during 6 months

Real-life experience with benralizumab during 6 months

Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, suf...

Full description

Bibliographic Details
Main Authors:	A. Padilla-Galo, RCh Levy-Abitbol, C. Olveira, B. Valencia Azcona, M. Pérez Morales, F. Rivas-Ruiz, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon
Format:	Article
Language:	English
Published:	BMC 2020-06-01
Series:	BMC Pulmonary Medicine
Subjects:	Asthma Benralizumab Eosinophils Biologics Severe asthma Eosinophilic asthma
Online Access:	http://link.springer.com/article/10.1186/s12890-020-01220-9

Similar Items

Real-life cost-effectiveness of benralizumab in patients with severe asthma
by: A. Padilla-Galo, et al.
Published: (2021-05-01)

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study
by: García-Moguel I, et al.
Published: (2022-05-01)

Efectividad de mepolizumab y benralizumab en una cohorte de pacientes con asma grave eosinofílico en vida real
by: María José Espinosa de los Monteros Garde, et al.
Published: (2021-04-01)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
by: Cristiano Caruso, et al.
Published: (2022-09-01)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01)

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
by: Eva Martínez-Moragón, et al.
Published: (2021-12-01)

Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumonia
by: Yoshiro Kai, et al.
Published: (2024-01-01)

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma
by: José A. Cañas, et al.
Published: (2021-01-01)

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings
by: M. V. Zhuravleva, et al.
Published: (2022-07-01)

Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report
by: Hideyasu Shimizu, et al.
Published: (2021-01-01)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
by: Caminati M, et al.
Published: (2019-05-01)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
by: Marco Caminati, et al.
Published: (2023-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
by: Alessandra Vultaggio, et al.
Published: (2023-05-01)

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab
by: Luisa Ricciardi, et al.
Published: (2022-04-01)

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
by: Cameli P, et al.
Published: (2024-03-01)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
by: Hiroaki Tsurumaki, et al.
Published: (2019-07-01)

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
by: Francesco Menzella, et al.
Published: (2022-02-01)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
by: Menzella F, et al.
Published: (2021-02-01)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
by: Takanori Numata, et al.
Published: (2020-08-01)

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis
by: Arvindran Alaga, et al.
Published: (2023-06-01)

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
by: Alicia Padilla-Galo, et al.
Published: (2023-09-01)

Autoimmune hepatitis with eosinophilic infiltration responsive to anti-interleukin-5 receptor treatment: a case report and literature review
by: Francesca Romana Ponziani, et al.
Published: (2023-10-01)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps
by: Rory Chan, et al.
Published: (2023-03-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
by: Maria D'Amato, et al.
Published: (2022-05-01)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
by: Maria Blomberg, et al.
Published: (2020-11-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
by: Sriram Sridhar, et al.
Published: (2019-01-01)

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
by: Senna G, et al.
Published: (2022-11-01)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
by: FitzGerald JM, et al.
Published: (2019-12-01)

New therapy options for patients with eosinophilic type of severe bronchial asthma
by: G. L. Ignatova, et al.
Published: (2020-01-01)

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)
by: Marco Contoli, et al.
Published: (2022-04-01)

IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma
by: Hideyasu Shimizu, et al.
Published: (2021-10-01)

Capturing patient-centered outcomes using innovative technologies in adults with severe eosinophilic asthma on benralizumab: Τhe EMPOWAIR real-world study design
by: Konstantinos Kostikas, et al.
Published: (2022-10-01)

Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study
by: Yamaguchi M, et al.
Published: (2024-01-01)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
by: Raffaele Campisi, et al.
Published: (2023-06-01)